19
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T79381 |
Galectin-3/galectin-8-IN-2
|
Galectin | Immunology/Inflammation |
Galectin-3/galectin-8-IN-2(Compound 57)是一种针对Galectin-3和galectin-8C末端结构域的双重抑制剂,其Kd值分别为12.8 μM和2.06 μM。该化合物能够抑制MRC-5肺成纤维细胞的迁移,适用于癌症和组织纤维化研究领域。 | |||
T79380 |
Galectin-3/galectin-8-IN-1
|
Galectin | Immunology/Inflammation |
Galectin-3/galectin-8-IN-1 (Compound 53) 是抑制Galectin-3和galectin-8C末端结构域的双重抑制剂,其Kd值分别为4.12 μM和6.04 μM。该化合物有效抑制MRC-5肺成纤维细胞的迁移,可用于癌症和组织纤维化的研究。 | |||
T82605 |
DB21, Galectin-1 Antagonist
|
Galectin | Immunology/Inflammation |
DB21, Galectin-1 Antagonist 是一种用于抑制galectin-1 (GAL1)与细胞表面聚糖结合的二苯并呋喃缀合肽模拟物。在黑色素瘤、肺腺癌和卵巢癌模型中,该化合物能增强血管生成和肿瘤生长的抑制效果。 | |||
T62454 |
Galectin-3-IN-1
|
||
Galectin-3-IN-1 (Compound 1) 是一种多价半乳糖凝集素-3 (Gal-3) 的有效抑制剂。其中 Galectin-3 参与许多与癌症相关的代谢过程。 | |||
T64040 | Galectin-3-IN-2 | ||
Galectin-3-IN-2 是多价半乳糖凝集素-3 的有效抑制剂,对 Gal-3 的 IC50 值为 8.3 μM。Galectin-3 可参与很多与癌症相关的代谢过程。 | |||
T61014 | Galectin-8-IN-1 | ||
Galectin-8-IN-1 是galectin-8N-末端结构域的选择性配体,Kd 值为 48 μM。Galectin-8-IN-1 的选择性是 galectin-3 的 15 倍,甚至优于其他哺乳动物的 galectins。 | |||
T74538 | Galectin-3 antagonist 2 | Galectin | Immunology/Inflammation |
Galectin-3,作为β-半乳糖苷特异性的识别蛋白(凝集素),具备促进B细胞前体急性淋巴细胞白血病(BCP-ALL)细胞迁移及耐受药物治疗的功能。 | |||
T16413 |
OTX008
Calixarene 0118,PTX008 |
Galectin | Immunology/Inflammation |
OTX008 (PTX008) 是半乳糖凝集素 1 选择性抑制剂。 | |||
T15372 |
GB1107
(2R,3R,4S,5R,6R)-2-(3,4-dichlorophenyl)sulfanyl-6-(hydroxymethyl)-4-[4-(3,4,5-trifluorophenyl)triazol-1-yl]oxane-3,5-diol |
Galectin | Immunology/Inflammation |
GB1107 是一种有效的选择性 Galectin-3 抑制剂,Kd 为 37 nM。 | |||
T5121 |
TD139
|
Galectin | Immunology/Inflammation |
TD139 是一种吸入型 galectin-3 抑制剂(Kd:14 nM)。 | |||
T11346L |
G3-C12 acetate(848301-94-0 free base)
|
Galectin | Immunology/Inflammation |
G3-C12 acetate(848301-94-0 free base) 显示出抗癌活性。是一种半乳糖凝集素 3 结合肽,Kd 为 88 nM。 | |||
T38074 |
Thiodigalactoside
|
Galectin | Immunology/Inflammation |
Thiodigalactoside 是一种具有口服活性的,有效的半乳凝素 (GAL) 抑制剂,对于 GAL-1 和 GAL-3 的 Kd 值分别为 24 μM,49 μM。Thiodigalactoside 是一种不可代谢的二糖,具有抗炎和抗癌活性。Thiodigalactoside 可显着降低饮食诱发的肥胖大鼠的体重增加。 | |||
T69874 | LLS30 | ||
LLS30 is an allosteric inhibitor of Galectin-1 (Gal-1). LLS30 decreases Gal-1 binding affinity to its binding partners, and potentially overcomes metastatic castration-resistant prostate cancer (mCRPC). | |||
T11346 |
G3-C12
|
Others | Others |
G3-C12 shows anticancer activity. is a galectin-3 binding peptide, with Kd of 88 nM. | |||
T75986 |
G3-C12 TFA
|
||
G3-C12 (TFA) 是 galectin-3 结合肽,Kd 值为 88 nM,具有抗肿瘤活性。 | |||
T16620 |
Propargyl-PEG5-acid
Propargyl-PEG4-C2-acid |
Others | Others |
Propargyl-PEG5-acid is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Propargyl-PEG5-acid can used to synthesize ADC inhibitors of Galectin-3[1]. | |||
TP1294 |
G3-C12 TFA (848301-94-0 free base)
G3-C12 TFA |
||
G3-C12 TFA Salt is a specific galectin-3 binding peptide with Ksubdsub of 88 nM and shows anticancer activity. | |||
T63485 |
Apoptosis inducer 8
|
||
Apoptosis inducer 8 是一种galectin-1 (gal-1)介导的凋亡 (apoptosis) 诱导剂,也是一种PET 显像剂,能够明显减少 gal-1 蛋白水平,可用于全球主要的肺癌的研究。 | |||
T16624 | Propargyl-PEG4-CH2CH2-Boc | Others | Others |
Propargyl-PEG4-CH2CH2-Boc is a PEG- and Alkyl/ether-based non-cleavable ADC linker. Propargyl-PEG5-Boc can used to synthesize ADC inhibitors of Galectin-3[1]. |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TQ0265 |
Indolelactic acid
|
Endogenous Metabolite | Metabolism |
Indolelactic acid 是 Azotobacter vinelandii 培养中的色氨酸分解代谢物。 |